Business Context and Reporting Period
Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2026
Reporting Period: Second quarter and six months ended June 30, 2026
This filing serves as a notification that the Company issued a press release and investor presentation materials regarding its consolidated financial results for the specified period. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) rather than the body of this 8-K.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached Press Release (Exhibit 99.1) and Investor Presentation (Exhibit 99.2).
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It only confirms the issuance of results for the second quarter and six months ended June 30, 2026.
Guidance, Outlook, and Risks
Management Commentary: The Company made investor presentation materials available on its website on August 5, 2026, which likely contain outlook and commentary, though the text of the presentation is not included in this summary.
Legal Status of Information: The information furnished in this Item 2.02 and Item 7.01, including the exhibits, is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 and YTD 2026 revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 (Investor Presentation) for management's forward-looking guidance and strategic outlook.
- Verify the specific details of any unusual items or contingencies mentioned in the full press release text.
- Confirm the Company's status as an emerging growth company (indicated as not applicable in the filing).